POM121B: A Potential Drug Target and Biomarker (G100288540)

Target Name: POM121B

NCBI ID: G100288540

POM121B

Other Name(s): POM121 transmembrane nucleoporin B (pseudogene)

POM121B: A Potential Drug Target and Biomarker

POM121B, also known as CSF-1, is a protein that is expressed in the cerebrospinal fluid (CSF) of individuals with multiple sclerosis (MS). It has been shown to be highly expressed in the CSF of individuals with MS, and it has been identified as a potential drug target in the treatment of MS.

The CSF is a clear and colorless liquid that surrounds the brain and spinal cord, providing essential cushioning and protection against mechanical shocks. It is produced by the cerebellum and is characterized by its high protein content. POM121B is one of the proteins that is present in the CSF of individuals with MS.

Multiple sclerosis is a chronic and unpredictable disease that affects the central nervous system. It is characterized by the immune system attacking the protective covering of nerve fibers, leading to communication problems and muscle weakness. There are several forms of MS, including relapsing-remitting MS and secondary progressive MS.

The treatment of MS is a significant public health issue, and there are currently several disease-modifying therapies (DMTs) available that can slow down the progression of the disease. However, the availability of these treatments is limited, and there is a high demand for new and more effective treatments.

POM121B has been identified as a potential drug target by researchers because it is expressed in the CSF of individuals with MS and has been shown to be involved in the immune response. POM121B is a key regulator of the immune response and has been shown to play a role in the development of MS.

In addition, POM121B has been shown to be involved in the regulation of pain perception and neuroinflammation. These factors may be involved in the development and progression of MS.

While further research is needed, POM121B is a promising target for the development of new treatments for MS. Researchers are currently studying the effects of different drugs on POM121B expression and its role in the treatment of MS.

In conclusion, POM121B is a protein that has been identified as a potential drug target for the treatment of MS. Further research is needed to determine its role in the development and progression of MS and to develop effective treatments.

Protein Name: POM121 Transmembrane Nucleoporin B (pseudogene)

Functions: Putative component of the nuclear pore complex (NPC). The repeat-containing domain may be involved in anchoring components of the pore complex to the pore membrane (By similarity)

The "POM121B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POM121B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets